The Right Molecules. Designed. Delivered.

Size: px

Start display at page:

Download "The Right Molecules. Designed. Delivered."

Edwin Sanders
6 years ago
Views:

1 The Right Molecules. Designed. Delivered.

400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered

2 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since In IND Stage 5 Entered Phase I Clinical Trials 2 Entered Phase II Clinical Trials 1 Entered Phase III Clinical Trials (Breakthrough Designation) IDSU by WuXi 01

3 IDSU by WuXi. Where Expertise Means Everything. The International Discovery Service Unit (IDSU) is WuXi s solution to address our industry s drug discovery challenges through expertise in medicinal chemistry and program management. We collaborate closely with our international customers ranging from pharma and biotech to academia to rapidly advance programs towards key inflection points and milestones by leveraging IDSU s peer-recognized expertise and WuXi s integrated platform from hit identification to preclinical candidate selection and beyond. With some of the industry s finest and most experienced medicinal chemists at WuXi, we aspire to become the partner-of-choice in externalized solutions to enable advancement of programs in ways that are both smarter and faster. Collaborative. Having delivered over 20 preclinical candidates since 2008 for our partners, we understand the unique challenges and needs of each program. We work closely with partners to establish strategy, customize resources and guide project execution to deliver on goals. WuXi s China Platform Execution of: HTS & Chemistry in vitro & in vivo Biology DMPK & Formulation Safety Assessment WuXi s IDSU Team Medicinal Chemistry Project Execution Program Management Partner Disease Biology Target of Interest Inhouse Expertise Efficient. We provide our customers with access to WuXi s best-in-class fully integrated drug discovery and development platform to seamlessly progress programs from target through to preclinical candidate selection and beyond. Protein crystallography FBDD and SBDD Modeling and Chemoinformatics Structural Biology and Computational >300 Employees Non-GLP and GLP Toxicokinetics and bioanalytical Safety Assessment and Toxicology Synthetic Chemistry Medicinal Chemistry Chemists Discovery to GMP Radiolabel Chemistry ADME and DMPK in vitro Biology & in vivo Pharmacology > 350 Scientists Rodents to NHPs Discovery to IND-enabling Metabolite ID Radiolabeled Studies > 350 Scientists Multiple biology screening platforms Electrophysiology HTS and compound collection Translational models Genomics Center (CLIA-certified) Biomarkers IDSU by WuXi 02

Meet the Team that Has Made Difference to Patients Global Expertise Local Connectivity Small molecule drug discovery requires a deep understanding of biological context coupled to knowledge and

4 Meet the Team that Has Made Difference to Patients Global Expertise Local Connectivity Small molecule drug discovery requires a deep understanding of biological context coupled to knowledge and experience of medicinal chemistry to make the right molecules to answer the right questions. WuXi has a powerful core of experienced, industry-seasoned drug hunters who are peer recognized including induction to the American Chemical Society Hall of Fame and recognition as Heroes of Chemistry by The American Chemical Society. Collectively, IDSU members have been named as inventors and authors on >750 patents and publications, and have made significant contributions to discovery projects throughout their careers, including blockbuster drugs that are profoundly improving patients lives. IDSU s highly experienced medicinal chemists are located in key biopharma clusters of the United States and Europe. These highly accomplished and industry-seasoned drug hunters function as a local resource to our valued partners. WuXi s local presence offers a range of advantages in program management, strategic planning in projects of the collaboration, and streamlining of communications with WuXi s China-based operations and execution teams. IDSU by WuXi 03

Richard Soll, PhD SVP and Head of IDSU 30+ years in drug

patents and publications Joe Vacca, PhD SVP of IDSU and Head

Heroes of Chemistry ; 100+ patents and publications Linus

years in drug discovery; 60+ patents and publications Tao

discovery; 80 patents and publications John Wai.

Honoree of ACS "Heroes of Chemistry" Craig Coburn.

5 Richard Soll, PhD SVP and Head of IDSU 30+ years in drug discovery; former CSO and Head of R&D at TargeGen; 130+ patents and publications Joe Vacca, PhD SVP of IDSU and Head of ESSP 30+ years at Merck; Honoree of ACS Hall of Fame and Heroes of Chemistry ; 100+ patents and publications Linus Lin, PhD VP of IDSU and VP of Operations & Chemistry 20+ years in drug discovery; 60+ patents and publications Tao Guo, PhD VP of Medicinal Chemistry 20+ years in drug discovery; 80 patents and publications John Wai. PhD VP of Medicinal Chemistry 24 yrs at Merck; Isentress ; Honoree of ACS "Heroes of Chemistry" Craig Coburn. PhD VP of Medicinal Chemistry 20 yrs at Merck; multiple candidates including Elbasvir (breakthrough HCV drug) IDSU by WuXi 04

Medchem Case Studies Osteoporosis OBJECTIVE: Discover a novel PCC candidate with better efficacy, PK and safety profiles than a competitor compound 17 months MILESTONE From patent literature to First

months Nomination within 24 months Antiviral OBJECTIVE: Discover the best-in-class compound with improved PK profiles 2 PCCs MILESTONE Discovered 2 PCCs 1 st PCC went to Phase I 2 nd PCC advanced to

6 Medchem Case Studies Osteoporosis OBJECTIVE: Discover a novel PCC candidate with better efficacy, PK and safety profiles than a competitor compound 17 months MILESTONE From patent literature to First PCC Nomination within 17 months Pain OBJECTIVE: Discover a novel PCC candidate with better efficacy, PK and safety profiles than a benchmark compound 24 MILESTONE From patent literature to First PCC months Nomination within 24 months Antiviral OBJECTIVE: Discover the best-in-class compound with improved PK profiles 2 PCCs MILESTONE Discovered 2 PCCs 1 st PCC went to Phase I 2 nd PCC advanced to Phase III CV/MED OBJECTIVE: Discover a novel PCC with better potency, PK, and safety profiles than a competitor s compounds 20 months MILESTONE Discovered a novel PCC within 20 months IDSU by WuXi 05

7 Enabling Platform We understand that each partner has different needs and internal capabilities. Working with IDSU enables our partners to access WuXi s industry-leading capability and technology platform in efficient and cost-effective ways. Our small molecule platform spans the entire R&D value chain from discovery to commercialization. Our laboratory services extend from in-depth discovery chemistry and biology to preclinical development including GLP toxicology and bioanalytical. Development and manufacturing services range from formulation and analytical R&D to GMP clinical drug product and commercial API manufacturing at our STA subsidiary. WuXi s Genome Center tackles challenges in personalized medicine, while clinical and regulatory services support our partners needs to conduct the highest-quality clinical trials in China for Chinese and international regulatory filings. IDSU by WuXi 06

8 International Discovery Service Unit The Right Molecules. Designed. Delivered. Contact Us IDSU Leadership Rich Soll Joe Vacca Linus Lin Tao Guo IDSU Business Development Declan Ryan US West Coast: Jennifer Milanovich US East Coast: Linda Zhao Europe: Rosie Hutchings

Antibody Discovery at Evotec

Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic